Foghorn Therapeutics (FHTX) POS AM Prospectus update (post-effective amendment)

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement No. 333-262711 on Form S-3 of our report dated March 10, 2022 relating to the consolidated financial statements of Foghorn Therapeutics, Inc. appearing in the Annual Report on Form 10-K of Foghorn Therapeutics, Inc. for the year ended December 31, 2021. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

April 15, 2022